Figure 1.
Synergistic platelet activation and aggregation induced by 5B9 and 1E12. (A) SRA performed with 5B9 and 1E12 incubated alone or together, without or with UFH, IV.3, or a control Ab. Data are the mean of serotonin release (n = 10). (B) SRA was performed with plasma samples from patients with HIT (n = 18) or with (C) nonpathogenic anti-PF4/H Abs (n = 18) and washed platelets from 4 healthy donors, without or with 1E12, control Ab, or UFH. (D) Whole blood platelet aggregation induced by 5B9 and 1E12 alone or together, without or with UFH or control Ab. Data are the mean of AUC (n = 23). Mann-Whitney U test was used to compare the different conditions tested. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001. The dotted line represents the cutoff value for SRA in panel A, B and C or whole blood platelet aggregation in panel D. AUC, area under the curve; ELISA, enzyme-linked immunosorbent assay.

Synergistic platelet activation and aggregation induced by 5B9 and 1E12. (A) SRA performed with 5B9 and 1E12 incubated alone or together, without or with UFH, IV.3, or a control Ab. Data are the mean of serotonin release (n = 10). (B) SRA was performed with plasma samples from patients with HIT (n = 18) or with (C) nonpathogenic anti-PF4/H Abs (n = 18) and washed platelets from 4 healthy donors, without or with 1E12, control Ab, or UFH. (D) Whole blood platelet aggregation induced by 5B9 and 1E12 alone or together, without or with UFH or control Ab. Data are the mean of AUC (n = 23). Mann-Whitney U test was used to compare the different conditions tested. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001. The dotted line represents the cutoff value for SRA in panel A, B and C or whole blood platelet aggregation in panel D. AUC, area under the curve; ELISA, enzyme-linked immunosorbent assay.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal